| Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study JM Michot, R Bouabdallah, U Vitolo, JK Doorduijn, G Salles, A Chiappella, ... The Lancet Haematology 7 (9), e649-e659, 2020 | 31 | 2020 |
| Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. ZA Wainberg, HS Hochster, B George, M Gutierrez, ME Johns, ... Journal of Clinical Oncology 35 (4_suppl), 412-412, 2017 | 31 | 2017 |
| Promotion time cure rate model with nonparametric form of covariate effects T Chen, P Du Statistics in medicine 37 (10), 1625-1635, 2018 | 20 | 2018 |
| nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial C Gridelli, T Chen, A Ko, ME O’Brien, TJ Ong, MA Socinski, PE Postmus Drug Design, Development and Therapy, 1445-1451, 2018 | 14 | 2018 |
| Nanoparticle albumin-bound paclitaxel plus carboplatin induction followed by nanoparticle albumin-bound paclitaxel maintenance in squamous non–small-cell lung cancer (ABOUND … DR Spigel, RM Jotte, SP Aix, L Gressot, D Morgensztern, M McCleod, ... Clinical lung cancer 22 (1), 6-15. e4, 2021 | 11 | 2021 |
| Avadomide (CC-122), a novel cereblon modulating agent, plus rituximab in patients with relapsed or refractory follicular lymphoma LJ Nastoupil, F Bijou, V Ribrag, JC Chavez, TE Witzig, DJ Andorsky, ... Blood 132, 1602, 2018 | 9 | 2018 |
| Mixture cure rate models with accelerated failures and nonparametric form of covariate effects T Chen, P Du Journal of Nonparametric Statistics 30 (1), 216-237, 2018 | 6 | 2018 |
| Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study. DM Waterhouse, JW Goldman, B George, PJ O'Dwyer, M Ye, T Chen, ... Journal of Clinical Oncology 35 (15_suppl), 9095-9095, 2017 | 3 | 2017 |
| nab-paclitaxel plus carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study DR Spigel, RM Jotte, S Ponce Aix, L Gressot, D Morgensztern, ... ANNALS OF ONCOLOGY 29, 2018 | 2 | 2018 |
| nab-paclitaxel+ carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND. sqm study DR Spigel, RM Jotte, SP Aix, L Gressot, D Morgensztern, M McCleod, ... Annals of Oncology 29, viii749-viii750, 2018 | 2 | 2018 |
| P1. 03-026 Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC JW Goldman, D Waterhouse, B George, P O'Dwyer, T Chen, N Trunova, ... Journal of Thoracic Oncology 12 (11), S1960-S1961, 2017 | 1 | 2017 |
| P1. 48: nab-Paclitaxel+ Carboplatin in advanced non-small cell lung cancer: outcomes in elderly patients with squamous histology: track: advanced NSCLC C Gridelli, T Chen, A Ko, TJ Ong, M O'Brien, M Socinski, P Postmus Journal of Thoracic Oncology 11 (10), S213, 2016 | 1 | 2016 |
| Effect of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer (NSCLC)(ABOUND. sqm) SP Aix, V Villaflor, J Knoble, M Thomas, J von Pawel, S Bailey, ... Annals of Oncology 28, v488, 2017 | | 2017 |
| nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer (NSCLC): Interim safety results from ABOUND. sqm C Gridelli, M McCleod, D Morgensztern, DB Daniel, R Page, T Wehler, ... Annals of Oncology 28, v489-v490, 2017 | | 2017 |
| nab-paclitaxel (nab-P)+ carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim safety results from the phase 3 ABOUND. sqm study OJ Vidal, D Daniel, M Johnson, J Knoble, T Chen, M McCleod, TJ Ong, ... Annals of Oncology 27, vi444, 2016 | | 2016 |
